Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant in Presumed NASH
NCT03823703Phase 2Terminated
- Sponsor
- Corcept Therapeutics
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of miricorilant in Nonalcoholic steatohepatitis (NASH), sponsored by Corcept Therapeutics. Primary endpoint: Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction at Day 95. Started Nov 2020; status: terminated.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03823703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823703.